Paul Tudor Jones Travere Therapeutics, Inc. Transaction History
Tudor Investment Corp Et Al
- $25.1 Billion
- Q4 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 43,213 shares of TVTX stock, worth $887,162. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,213
Previous 38,144
13.29%
Holding current value
$887,162
Previous $533,000
41.09%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding TVTX
# of Institutions
214Shares Held
94.3MCall Options Held
1.2MPut Options Held
778K-
Black Rock Inc. New York, NY7.64MShares$157 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.36MShares$151 Million1.81% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.74MShares$138 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.97MShares$102 Million3.46% of portfolio
-
Macquarie Group LTD Australia, C34.26MShares$87.4 Million0.09% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.32B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...